Breast Cancer Clinical Trials & Research at Providence Medical Group
In the U.S., breast cancer is the second most common cancer in women after
skin cancer. It can occur in both men and women. The most common type
of breast cancer is ductal carcinoma, which begins in the cells of the
ducts. Breast cancer can also begin in the cells of the lobules and in
other tissues in the breast. Invasive breast cancer is breast cancer that
has spread from where it began in the ducts or lobules to surrounding tissue.
Providence Medical Group is currently enrolling patients for the following
breast cancer clinical trials:
A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally
Recurrent Breast Cancer Patients in Combination with Pembrolizumab (BriaCell
Rollover) - ON HOLD
Treatment agent: SV-BR-1-GM + Pembrolizumab
PI:
Jarrod Holmes, MD
Study Coordinator: Kim
Resources and Links:
clinicaltrials.gov NCT No: NCT03328026
An Open-label Multicenter Study Evaluating the Safety of Lasofoxifene in
Combination with Abemaciclib for the treatment of Pre- and Postmenopausal
Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and
have an ESR1 MutationAn
Treatment agent: Lasofoxifene and abemaciclib
PI:
Ian Anderson, MD
Study Coordinator: Camille Shaffer //
Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04432454